Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy

Journal of Infectious Diseases

Volumn 213, Issue 10, 2016, Pages 1532-1540

  Papp, Eszter ^a   Balogun, Kayode ^a   Banko, Nicole ^a   Mohammadi, Hakimeh ^a   Loutfy, Mona ^b,c   Yudin, Mark H ^c,e   Shah, Rajiv ^e   Macgillivray, Jay ^e   Murphy, Kellie E ^c,f   Walmsley, Sharon L ^a,c   Silverman, Michael ^g   Serghides, Lena ^a,b,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c Department of Medicine ^*  (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

20 hydroxysteroid dehydrogenase; Adverse birth outcomes; Antiretrovirals; Birth weight; HIV; Pregnancy; Progesterone; Prolactin; Protease inhibitors

Indexed keywords

20ALPHA HYDROXYSTEROID DEHYDROGENASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MARKER; MESSENGER RNA; METASTATIC LYMPH NODE 64 PROTEIN; PROGESTERONE; PROLACTIN; RITONAVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIRTH WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PLACENTA; PREGNANT WOMAN; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGESTERONE METABOLISM; PROLACTIN BLOOD LEVEL; SIDE EFFECT; TROPHOBLAST; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYMOLOGY; HIV INFECTIONS; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; ANIMALS; ANTI-HIV AGENTS; CELLS, CULTURED; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; LOPINAVIR; MICE; MICE, INBRED C57BL; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGESTERONE; PROLACTIN; RITONAVIR; TROPHOBLASTS; ZIDOVUDINE;

EID: 84970021359     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw004     Document Type: Article

References (50)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
2. Mahy M, Stover J, Stanecki K, Stoneburner R, Tassie JM. Estimating the impact of antiretroviral therapy: regional and global estimates of life-years gained among adults. Sex Transm Infect 2010; 86(suppl 2):ii67-71.
3. World Health Organization. World Health Organization global health report 2013. Geneva; World Health Organization, 2013.
4. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705.
5. Bagkeris E, Malyuta R, Volokha A, et al. Pregnancy outcomes in HIV-positive women in Ukraine, 2000-12 (European Collaborative Study in EuroCoord): an observational cohort study. Lancet HIV 2015; 2:e385-92.
6. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21:607-15.
7. Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS 2013; 8:504-10.
8. Short CE, Taylor GP. Antiretroviral therapy and preterm birth in HIV-infected women. Expert Rev Anti Infect Ther 2014; 12:293-306.
9. Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note of caution. J Infect Dis 2012; 206:1639-41.
10. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland: World Health Organization, 2013.
11. Chougrani I, Luton D, Matheron S, Mandelbrot L, Azria E. Safety of protease inhibitors in HIV-infected pregnant women. HIV AIDS (Auckl) 2013; 5:253-62.
12. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIVinfected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-14.
13. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348-60.
14. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18:2337-9.
15. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193:1195-201.
16. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 2008; 22:1815-20.
17. Ravizza M, Martinelli P, Bucceri A, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195:913-4; author reply 6-7.
18. Elson J, Salim R, Tailor A, Banerjee S, Zosmer N, Jurkovic D. Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo. Ultrasound Obstet Gynecol 2003; 21:57-61.
19. Lachelin GC, McGarrigle HH, Seed PT, Briley A, Shennan AH, Poston L. Low saliva progesterone concentrations are associated with spontaneous early preterm labour (before 34 weeks of gestation) in women at increased risk of preterm delivery. BJOG 2009; 116:1515-9.
20. Cousins LM, Hobel CJ, Chang RJ, Okada DM, Marshall JR. Serum progesterone and estradiol-17beta levels in premature and term labor. Am J Obstet Gynecol 1977; 127:612-5.
21. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015; 211:10-8.
22. Lydon JP, DeMayo FJ, Funk CR, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995; 9:2266-78.
23. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal contraceptives. Expert Opin Drug Metab Toxicol 2013; 9:559-72.
24. Higaki Y, Usami N, Shintani S, Ishikura S, El-Kabbani O, Hara A. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 2003; 143-144:503-13.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
26. Drewlo S, Levytska K, Kingdom J. Revisiting the housekeeping genes of human placental development and insufficiency syndromes. Placenta 2012; 33:952-4.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8.
28. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
29. Tuckey RC, Bose HS, Czerwionka I, Miller WL. Molten globule structure and steroidogenic activity of N-218 MLN64 in human placental mitochondria. Endocrinology 2004; 145:1700-7.
30. Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32:81-151.
31. Bao L, Tessier C, Prigent-Tessier A, et al. Decidual prolactin silences the expression of genes detrimental to pregnancy. Endocrinology 2007; 148:2326-34.
32. Dola CP, Khan R, DeNicola N, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med 2011; 40:51-5.
33. Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis 2013; 207:612-21.
34. Ades V, Mwesigwa J, Natureeba P, et al. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda. J Trop Pediatr 2013; 59:441-6.
35. Ishida M, Choi JH, Hirabayashi K, et al. Reproductive phenotypes in mice with targeted disruption of the 20alpha-hydroxysteroid dehydrogenase gene. J Reprod Dev 2007; 53:499-508.
36. Matsuda J, Noda K, Shiota K, Takahashi M. Participation of ovarian 20 alphahydroxysteroid dehydrogenase in luteotrophic and luteolytic processes during rat pseudopregnancy. J Reprod Fertil 1990; 88:467-74.
37. Waddell BJ, Pepe GJ, Albrecht ED. Progesterone and 20 alpha-hydroxypregn-4-en-3-one (20 alpha-OHP) in the pregnant baboon: selective placental secretion of 20 alpha-OHP into the fetal compartment. Biol Reprod 1996; 55:854-9.
38. Thau R, Lanman JT, Brinson A. Declining plasma progesterone concentration with advancing gestation in blood from umbilical and uterine veins and fetal heart in monkeys. Biol Reprod 1976; 14:507-9.
39. Albarracin CT, Parmer TG, Duan WR, Nelson SE, Gibori G. Identification of a major prolactin-regulated protein as 20 alpha-hydroxysteroid dehydrogenase: coordinate regulation of its activity, protein content, and messenger ribonucleic acid expression. Endocrinology 1994; 134:2453-60.
40. Zhong L, Parmer TG, Robertson MC, Gibori G. Prolactin-mediated inhibition of 20alpha-hydroxysteroid dehydrogenase gene expression and the tyrosine kinase system. Biochem Biophys Res Commun 1997; 235:587-92.
41. Stocco CO, Zhong L, Sugimoto Y, Ichikawa A, Lau LF, Gibori G. Prostaglandin F2alpha-induced expression of 20alpha-hydroxysteroid dehydrogenase involves the transcription factor NUR77. J Biol Chem 2000; 275:37202-11.
42. Roberson AE, Hyatt K, Kenkel C, Hanson K, Myers DA. Interleukin 1beta regulates progesterone metabolism in human cervical fibroblasts. Reprod Sci 2012; 19:271-81.
43. Williams KC, Renthal NE, Condon JC, Gerard RD, Mendelson CR. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc Natl Acad Sci U S A 2012; 109:7529-34.
44. Montero A, Fernandez MA, Cohen JE, Luraghi MR, Sen L. Prolactin levels in the cerebrospinal fluid of patients with HIV infection and AIDS. Neurol Res 1998; 20:2-4.
45. Orlando G, Brunetti L, Vacca M. Ritonavir and Saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Int J Immunopathol Pharmacol 2002; 15:65-8.
46. Handwerger S, Markoff E, Richards R. Regulation of the synthesis and release of decidual prolactin by placental and autocrine/paracrine factors. Placenta 1991; 12:121-30.
47. Devi YS, Halperin J. Reproductive actions of prolactin mediated through short and long receptor isoforms. Mol Cell Endocrinol 2014; 382:400-10.
48. Horseman ND, Zhao W, Montecino-Rodriguez E, et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997; 16:6926-35.
49. Yang X, Meyer K, Friedl A. STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis. J Biol Chem 2013; 288:21184-96.
50. Frasor J, Gibori G. Prolactin regulation of estrogen receptor expression. Trends Endocrinol Metab 2003; 14:118-23.